Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Raffaele Ciampi, … , James A. Fagin, Yuri E. Nikiforov
Raffaele Ciampi, … , James A. Fagin, Yuri E. Nikiforov
Published January 3, 2005
Citation Information: J Clin Invest. 2005;115(1):94-101. https://doi.org/10.1172/JCI23237.
View: Text | PDF
Article Oncology

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

  • Text
  • PDF
Abstract

Genes crucial for cancer development can be mutated via various mechanisms, which may reflect the nature of the mutagen. In thyroid papillary carcinomas, mutations of genes coding for effectors along the MAPK pathway are central for transformation. BRAF point mutation is most common in sporadic tumors. By contrast, radiation-induced tumors are associated with paracentric inversions activating the receptor tyrosine kinases RET and NTRK1. We report here a rearrangement of BRAF via paracentric inversion of chromosome 7q resulting in an in-frame fusion between exons 1–8 of the AKAP9 gene and exons 9–18 of BRAF. The fusion protein contains the protein kinase domain and lacks the autoinhibitory N-terminal portion of BRAF. It has elevated kinase activity and transforms NIH3T3 cells, which provides evidence, for the first time to our knowledge, of in vivo activation of an intracellular effector along the MAPK pathway by recombination. The AKAP9-BRAF fusion was preferentially found in radiation-induced papillary carcinomas developing after a short latency, whereas BRAF point mutations were absent in this group. These data indicate that in thyroid cancer, radiation activates components of the MAPK pathway primarily through chromosomal paracentric inversions, whereas in sporadic forms of the disease, effectors along the same pathway are activated predominantly by point mutations.

Authors

Raffaele Ciampi, Jeffrey A. Knauf, Roswitha Kerler, Manoj Gandhi, Zhaowen Zhu, Marina N. Nikiforova, Hartmut M. Rabes, James A. Fagin, Yuri E. Nikiforov

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
BRAF
is recombined with the AKAP9
gene and results in expression of a fu...
BRAF is recombined with the AKAP9 gene and results in expression of a fusion protein. (A) Sequence of the 5′ RACE product showing a fusion point between AKAP9 and BRAF. (B) Confirmation of the reciprocal fusion by FISH with probes corresponding to the BRAF (red) and AKAP9 (green) genes. (C) The fusion is a result of paracentric chromosomal inversion inv(7)(q21–22q34). Chr., chromosome. (D) Genomic structure of the BRAF and AKAP9 genes showing the location of breakpoints (arrows) and the organization of the chimeric cDNA. Exons are represented by boxes and introns by lines. Numbers above indicate exon numbers. (E) Western blot analysis using BRAF antibody (left) and AKAP9 antibody (right), showing an approximately 170-kDa protein, corresponding to the predicted molecular weight of the fusion protein in the index case (number 02-28). Three other papillary carcinomas (T1–T3) are shown for comparison. Wild-type AKAP9 is 453 kDa in size and was not detected in this Western blot.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts